Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

201. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials

Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials Berg H, Lindgren P, Spiesser J, Parry D, Jonsson B Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated two treatment options for patients with ST-segment elevation myocardial infarction (STEMI). The options were clopidogrel in combination with acetylsalicylic acid (ASA) and ASA alone. Type

NHS Economic Evaluation Database.2007

202. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention

Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention Heeg B M, Peters R J, Botteman M, van Hout B A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the use of short-term versus long-term therapy with clopidogrel, in patients undergoing percutaneous coronary intervention, either electively or as patients with acute coronary syndrome. The authors concluded that long-term clopidogrel resulted in cost savings and increased the number of life-years and QALYs gained compared with short-term clopidogrel treatment

NHS Economic Evaluation Database.2007

203. Clopidogrel after drug-eluting stent implantation

Clopidogrel after drug-eluting stent implantation Clopidogrel after drug-eluting stent implantation | Therapeutics Initiative Independent Healthcare Evidence > > Clopidogrel after drug-eluting stent implantation Background information of the condition: Drug Eluting Stents (DES) Implantation DES were invented to reduce restenosis compared to bare metal stents (8% vs. 25% , respectively). The process responsible for stent stenosis is delayed with drugs (sirolimus [rapamycin] and paclitaxel (...) ); however this benefit is offset by harm due to stent thrombosis (0.2-1.1%). Dual antiplatelet therapy is recommended to decrease the rate of stent thrombosis. Drug (Product Monograph ) Category Clopidogrel is categorized as platelet aggregation inhibitor. Mechanism of action : Clopidogrel selectively inhibits the binding of ADP to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein IIb-IIIa complex, thereby inhibiting platelet aggregation. Indication : Clopidogrel

Therapeutics Letter2007

204. Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial

Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial Kolm P, Yuan Y, Veledar E, Mehta S R, O'Brien J A, Weintraub W S Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the long-term cost-effectiveness of clopidogrel plus acetylsalicylic acid (ASA) compared with ASA alone. The authors concluded that clopidogrel plus ASA therapy was cost-effective compared with ASA alone. Overall the methodology was good

NHS Economic Evaluation Database.2007

205. Should clopidogrel be stopped prior to urgent cardiac surgery?

Should clopidogrel be stopped prior to urgent cardiac surgery? BestBets: Should clopidogrel be stopped prior to urgent cardiac surgery? Should clopidogrel be stopped prior to urgent cardiac surgery? Report By: Babu Kunadian, Andrew R. Thornley, Marios Tanos - Cardiothoracic Registrars Search checked by Joel Dunning - Cardiothoracic Registrar RCS Institution: Department of Cardiothoracic Surgery, James Cook University Hospital and Freeman Hospital, Newcastle-upon-Tyne Date Submitted: 18th (...) September 2006 Date Completed: 26th October 2006 Last Modified: 18th September 2006 Status: Green (complete) Three Part Question In patients undergoing [urgent Coronary Arterial Bypass grafting] can surgery [with recent clopidogrel administration] be safely performed [early without excessive bleeding] Clinical Scenario You have been asked to perform urgent CABG on a 72 year old gentleman who has just undergone angiography for acute coronary syndrome. He had been admitted that day with chest pain at rest

BestBETS2007

207. Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Prasugrel versus clopidogrel in patients with acute coronary syndromes. 17982182 2007 11 16 2007 11 21 2015 11 19 1533-4406 357 20 2007 Nov 15 The New England journal of medicine N. Engl. J. Med. Prasugrel versus clopidogrel in patients with acute coronary syndromes. 2001-15 Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. To compare prasugrel, a new (...) thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding

NEJM2007

208. Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients

Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Article Text Therapeutics Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Free Walter L Peterson , MD Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2006

209. Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy

Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy Article Text Therapeutics Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy Free Steven

Evidence-Based Medicine (Requires free registration)2006

210. Clopidogrel plus aspirin or aspirin alone in unstable angina

Clopidogrel plus aspirin or aspirin alone in unstable angina BestBets: Clopidogrel plus aspirin or aspirin alone in unstable angina Clopidogrel plus aspirin or aspirin alone in unstable angina Report By: Shweta Gidwani - Clinical Effectiveness Fellow Search checked by Richard Body - Clinical Research Fellow Institution: Manchester Royal Infirmary Original author: Shweta Gidwani Original institution: Manchester Royal Infirmary Date Submitted: 25th November 2005 Date Completed: 2nd February 2006 (...) Last Modified: 1st December 2005 Status: Green (complete) Three Part Question In [patients suspected to have unstable angina] is [the use of clopidogrel plus asprin better than asprin alone] at [improving cardiovascular outcome] Clinical Scenario A 55 year old man, known to have angina, presents to the Emergency Department with new-onset typical ischaemic rest pain that is not relieved by his nitrate spray at home. His ECG shows ST depression in V3-V6. He is haemodynamically stable. You treat him

BestBETS2006

211. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK

A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK Karnon J, Bakhai A, Brennan A, Pandor A, Flather M, Warren E, Gray D, Akehurst R Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined 1-year of treatment with 75 mg/day clopidogrel (with a 300-mg loading dose), an adenosine diphosphate receptor antagonist, in the treatment of non-ST-segment-elevation acute coronary syndrome (ACS). Type of intervention Secondary

NHS Economic Evaluation Database.2006

212. Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases

Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Clopidogrel vs. acetylsalicylic acid in the secondary prophylaxis of vascular diseases. Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). 2006 Authors' objectives The aims of this evaluation were: 1. the comparative evaluation of the benefits and harms of clopidogrel and ASA as antiplatelet monotherapy for secondary prevention in patients

Health Technology Assessment (HTA) Database.2006

213. Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis

Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis Article Text Therapeutics Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death

Evidence-Based Medicine (Requires free registration)2006

214. Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation

Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Article Text Therapeutics Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation Statistics from

Evidence-Based Medicine (Requires free registration)2006

215. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. 16533938 2006 04 05 2006 04 12 2016 10 17 1538-3598 295 13 2006 Apr 05 JAMA JAMA Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. 1531-8 No specifically designed studies have addressed the role of the glycoprotein IIb (...) /IIIa inhibitor abciximab in patients with non-ST-segment elevation acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with 600 mg of clopidogrel. To assess whether abciximab is associated with clinical benefit in high-risk patients with ACS undergoing PCI after pretreatment with 600 mg of clopidogrel. International, multicenter, randomized, double-blind, placebo-controlled study conducted from March 2003 through December 2005, enrolling 2022

JAMA2006

216. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. 16531616 2006 04 20 2006 04 26 2016 08 03 1533-4406 354 16 2006 Apr 20 The New England journal of medicine N. Engl. J. Med. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. 1706-17 Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. We randomly assigned (...) 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) or placebo plus low-dose aspirin and followed them for a median of 28 months. The primary efficacy end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes. The rate of the primary efficacy end point was 6.8 percent with clopidogrel plus aspirin and 7.3 percent with placebo plus aspirin

NEJM2006

217. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. 16765759 2006 06 12 2006 06 22 2016 11 24 1474-547X 367 9526 2006 Jun 10 Lancet (London, England) Lancet Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE (...) W): a randomised controlled trial. 1903-12 Oral anticoagulation therapy reduces risk of vascular events in patients with atrial fibrillation. However, long-term monitoring is necessary and many patients cannot achieve optimum anticoagulation. We assessed whether clopidogrel plus aspirin was non-inferior to oral anticoagulation therapy for prevention of vascular events. Patients were enrolled if they had atrial fibrillation plus one or more risk factor for stroke, and were randomly allocated

Lancet2006

218. Clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases

Clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases Clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases 1 - Final report - [Commission No. A04-01A] 1 Publication date of the English translation: 04 October 2006. This translation is based on the German final report “Clopidogrel versus Acetylsalicylsäure in der Sekundärprophylaxe vaskulärer Erkrankungen” (Version 1.0, 30 June 2006). Please note: The translation (...) is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Final report A04-01A: Clopidogrel versus ASA for secondary prevention of vascular diseases 2 Topic: Evaluation of the benefits and harms of clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases Contracting agency: Federal Joint Committee (Gemeinsamer Bundesausschuss) Date of Commission: 15 December 2004 Internal

Institute for Quality and Efficiency in Healthcare (IQWiG)2006

219. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. BACKGROUND: Although clopidogrel plus aspirin is more effective than aspirin alone in preventing subsequent vascular events in patients with unstable angina, the cost-effectiveness of this combination has yet to be examined in this high-risk population. OBJECTIVE: To determine the cost-effectiveness of clopidogrel plus aspirin compared (...) with aspirin alone. DESIGN: Cost-utility analysis. DATA SOURCES: Published literature. TARGET POPULATION: Patients with unstable angina and electrocardiographic changes or non-Q-wave myocardial infarction. time horizon: Lifetime. PERSPECTIVE: Societal. INTERVENTIONS: Combination therapy with clopidogrel, 75 mg/d, plus aspirin, 325 mg/d, for 1 year, followed by aspirin monotherapy, was compared with lifelong aspirin therapy, 325 mg/d. OUTCOME MEASURES: Lifetime costs, life expectancy in quality-adjusted

Annals of Internal Medicine2005

220. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention

Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention Cowper P A, Udayakumar K, Sketch M H, Peterson E D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The prolongation of clopidogrel therapy from one month to one year after percutaneous coronary intervention (PCI) in unselected patients was examined. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical, unselected, heterogeneous cohort of patients treated

NHS Economic Evaluation Database.2005